The treatment of brain diseases has long been a challenge in medicine. The blood-brain barrier (BBB) is a natural defense that prevents most drugs from effectively reaching the brain. While essential for protecting the central nervous system, the BBB complicates drug development, to a clinical translation rate for brain therapeutics that is significantly lower than in other fields. That gap has kept delivery research active for decades: if a molecule cannot reach its target at a useful concentration, potency measured in vitro does not transfer to the patient.
Delivery strategies fall into three families, and each trades invasiveness against the concentration it can achieve at the target. Non-invasive routes accept low brain exposure in exchange for safety and repeat dosing. Localized invasive techniques achieve high local concentrations at the cost of a procedure. Bioengineering-based systems try to borrow a biological transport route that the BBB already permits. This article covers the definitions, advantages, and clinical potential of these delivery strategies in brain disease therapy.
1. Non-Invasive Drug Delivery Routes
Non-invasive drug delivery methods administer medications to the brain through nasal, oral mucosal, inhalation, or transdermal routes. By avoiding surgical intervention, these approaches improve patient compliance and bypass first-pass metabolism and gastrointestinal degradation, thereby enhancing drug bioavailability and efficacy.
Nasal Delivery: The highly vascularized nasal mucosa allows drugs to bypass the BBB via the olfactory and trigeminal nerves. Notable examples include Zavzpret, a nasal spray for migraine treatment, and emerging exosome-based nasal sprays for Alzheimer's disease.
Oral Mucosal Delivery: The rich capillary network in the oral mucosa facilitates rapid absorption while bypassing gastrointestinal breakdown. For instance, Kynmobi, a sublingual apomorphine film, is used to treat acute "off" episodes in Parkinson's disease.
Inhalation Delivery: Drugs administered via pulmonary mucosa rapidly enter the bloodstream. Adasuve, an inhaled powder formulation of loxapine, provides rapid control of acute agitation.
Transdermal Delivery: This method maintains steady plasma drug levels through sustained release. The Adlarity patch, delivering donepezil weekly, has gained popularity for its convenience in Alzheimer's disease management.
The common thread is that these routes reach the brain through a surface rather than through the circulation alone, and the fraction that arrives is usually small. That limits the payload to potent molecules, and it is why non-invasive programs tend to focus on acute or symptomatic indications where a modest central exposure is enough. These methods also improve patient experience and show significant potential in treating neurodegenerative and acute brain disorders.
2. Invasive Localized Drug Delivery Routes
Invasive localized drug delivery methods bypass the BBB by directly administering drugs to specific brain regions. These techniques achieve high local drug concentrations and include intraventricular injection, convection-enhanced delivery (CED), and intrathecal injection.
Intraventricular Injection: This method involves surgically implanted reservoirs to deliver drugs into the brain's ventricles, used for diseases where large molecules struggle to cross the BBB, such as Brineura for neuronal ceroid lipofuscinosis type 2.
Intrathecal Injection: Administering drugs into the cerebrospinal fluid via the subarachnoid space ensures widespread brain distribution. Intrathecal rituximab has shown efficacy in refractory anti-NMDAR encephalitis, significantly reducing cerebrospinal fluid antibody titers.
Convection-Enhanced Delivery (CED): This technique employs pressure-driven infusion to achieve precise, uniform drug distribution within brain lesions. CED is particularly effective for localized brain conditions such as Parkinson's disease and glioblastoma. In Parkinson's therapy, CED has been used to deliver glial cell line-derived neurotrophic factor (GDNF) via adeno-associated viral vectors to the putamen, restoring dopaminergic function. In glioblastoma, CED delivers drugs via micro-infusion pumps directly to the tumor site, reducing systemic side effects and improving local drug concentration.
Diffusion-based delivery results in a limited area of distribution and reflux along the needle track. Increased fl ow rate with CED results in a pressurized extracellular bulk flow that allows for a more homogeneous distribution of molecules/particles and increased distances from the cannula tip. Reflux is also reduced, especially with the step cannula design resulting in increased volume of distribution Nash, Kevin R., and Marcia N. Gordon. 'Convection enhanced delivery of recombinant adeno-associated virus into the mouse brain.' Gene Therapy for Neurological Disorders: Methods and Protocols (2016): 285-295.
CED stands out for its precision and effectiveness in treating brain diseases, and its clinical potential will expand with advancements in imaging-guided techniques. The distinction in the figure is worth keeping in mind: simple diffusion delivers a bolus that spreads a short distance and then retreats up the needle track, whereas pressure-driven infusion establishes a bulk flow through the extracellular space.
3. Emerging Drug Delivery Systems
Emerging drug delivery systems leverage advances in bioengineering and material sciences to achieve targeted and efficient brain drug delivery through receptor-mediated transcytosis, cell homing effects, and ultrasound-assisted techniques.
Receptor-Mediated Transcytosis: This system uses receptors like transferrin to transport large molecules across the BBB. Izcargo, developed for mucopolysaccharidosis, exemplifies the potential of this strategy.
Cell Homing Technologies: Leveraging the natural migratory abilities of immune cells, these technologies target inflamed brain regions. MAT2203, an antifungal agent, effectively treats cryptococcal meningitis by enhancing efficacy while reducing peripheral toxicity.
Ultrasound-Assisted Delivery: Focused ultrasound temporarily and reversibly disrupts the BBB, facilitating large molecule entry. The combination of aducanumab with ultrasound has shown promise in clearing amyloid-beta plaques in Alzheimer's disease.
What these three approaches share is that they use a transport mechanism the brain already has, rather than forcing a molecule through the barrier. Transcytosis moves cargo across endothelial cells, cell homing follows an inflammatory gradient, and ultrasound opens tight junctions for a period that closes again. Each adds a control variable that has to be characterized before the route can be used routinely.
These systems offer the potential to overcome the limitations of traditional delivery methods, providing new avenues for precision and personalized brain disease treatment.
Research in brain drug delivery represents not only a technological advance but also a response to patient needs. From optimizing non-invasive delivery routes like nasal, oral, inhalation, and transdermal methods to achieving precision through intraventricular injection, CED, and intrathecal administration, each technique advances brain disease therapy. Moreover, receptor-mediated systems, cell homing technologies, and ultrasound-assisted delivery present new strategies for individualized treatment and precision medicine.
As advancements in biomaterials, nanotechnology, and imaging continue, drug delivery will become more efficient, safe, and personalized, benefiting more patients. The pursuit of overcoming the BBB is reshaping the possibilities for brain disease treatment, and it keeps neuroscience delivery work tied to imaging, because a route that cannot be verified in situ cannot be dosed reproducibly.
